<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04918030</url>
  </required_header>
  <id_info>
    <org_study_id>2020YLK14</org_study_id>
    <nct_id>NCT04918030</nct_id>
  </id_info>
  <brief_title>STaged Interventional Strategies for Acute ST-seGment Elevation Myocardial Infarction Patient With Multi-vessel Disease（STAGED）</brief_title>
  <official_title>STaged Interventional Strategies for Acute ST-seGment Elevation Myocardial Infarction Patient With Multi-vessel Disease （STAGED）</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xiamen Cardiovascular Hospital, Xiamen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xiamen Cardiovascular Hospital, Xiamen University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      An investigator-initiated, randomized, multicenter, two-arm, open-label study of consecutive&#xD;
      patients presenting with STEMI and MVD Objectives: The present study aimed to investigate the&#xD;
      difference in all-cause mortality after in-hospital staged PCI versus out-hospital staged PCI&#xD;
      for ST-segment elevated myocardial infarction （STEMI）patients with multi-vessel Disease（MVD）&#xD;
      Background: In primary percutaneous coronary intervention for STEMI with MVD, complete&#xD;
      revascularization has proved to reduce the risk of cardiovascular death and myocardial&#xD;
      infarction. However, a strategy of nonculprit-vessel PCI with the goal of complete&#xD;
      revascularization still not to be confirmed. Compare with in-hospital staged PCI,&#xD;
      out-hospital PCI as a strategy of nonculprit-vessel PCI for STEMI patients with MVD might&#xD;
      have be beneficial results.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A total of 1700 subjects with STEMI who met inclusion criteria and do not have any exclusion&#xD;
      criterion will be randomized to in-hospital staged PCI group and out-hospital staged PCI&#xD;
      group. After successful percutaneous coronary intervention for culprit lesion, all&#xD;
      non-culprit vessel with significant lesion defined at least 80% diameter stenosis by visual&#xD;
      estimation and accompanied by a QFR measurement of less than or equal to 0.80 will be&#xD;
      performed complete revascularization.&#xD;
&#xD;
        1. Patients randomized to in-hospital staged PCI will have treated during the index&#xD;
           procedure (7±3 days), after revascularization of the culprit lesion, all significant&#xD;
           non-culprit coronary lesions.&#xD;
&#xD;
        2. Patients randomized to out-hospital staged complete revascularization will have treated&#xD;
           during the index procedure only the culprit lesion, and they will be hospitalized in&#xD;
           30±15 days for complete revascularization of all significant non-culprit coronary&#xD;
           lesions.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 11, 2021</start_date>
  <completion_date type="Anticipated">May 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>all-cause mortality</measure>
    <time_frame>12 months</time_frame>
    <description>The difference in all-cause mortality will be calculated from 0 month to 12 months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major adverse cardiovascular and cerebrovascular events (MACE)</measure>
    <time_frame>12 months</time_frame>
    <description>The difference in MACCE will be calculated from 1 month to 12 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>contrast-induced nephropathy（CIN）</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dosimetry calculation</measure>
    <time_frame>Immediately after PCI</time_frame>
    <description>The amount of X-ray exposure shown by the DSA</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1700</enrollment>
  <condition>STEMI</condition>
  <condition>Multi Vessel Coronary Artery Disease</condition>
  <condition>Percutaneous Coronary Intervention</condition>
  <arm_group>
    <arm_group_label>In-hospital staged PCI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients randomized to in-hospital staged PCI will have treated during the index procedure (7±3 days), after revascularization of the culprit lesion, all significant non-culprit coronary lesions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Out-hospital staged PCI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients randomized to out-hospital staged complete revascularization will have treated during the index procedure only the culprit lesion, and they will be hospitalized in 30±15 days for complete revascularization of all significant non-culprit coronary lesions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>In-hospital staged PCI</intervention_name>
    <description>After revascularization of the culprit lesion, all significant non-culprit vessel will be complete revascularzed during index the index procedure (7±3 day).</description>
    <arm_group_label>In-hospital staged PCI</arm_group_label>
    <other_name>Percutaneous coronary intervention</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Out-hospital staged PCI</intervention_name>
    <description>During the index procedure, patients will have treated with primary PCI the culprit lesion only. Patients will be hospitalized again after 30±15 days to undergo PCI of the other significant coronary lesions.</description>
    <arm_group_label>Out-hospital staged PCI</arm_group_label>
    <other_name>Percutaneous coronary intervention</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Provision of informed consent prior to any study specific procedures;&#xD;
&#xD;
          -  Established indication to PPCI according to the guidelines of American Heart&#xD;
             Association and American College of Cardiology;&#xD;
&#xD;
          -  Spontaneous acute STEMI (patients presenting within 24 hours of symptom onset) with&#xD;
             MVD after successful revascularization of the culprit artery;&#xD;
&#xD;
          -  De novo coronary lesion,&#xD;
&#xD;
          -  TIMI Flow 3 ( Cases with TIMI flow 2 need to perform angiographic again in 24h ensured&#xD;
             TIMI flow 3 for enrolling case )after revascularization of the culprit artery,&#xD;
             residual stenosis ≤20% and no coronary dissection greater than or equal to type C&#xD;
             leading to (threatening) vessel closure.&#xD;
&#xD;
          -  At least one non-culprit coronary stenosis ≥ 80% and accompanied by QFR ≤0.8 in a&#xD;
             vessel with a lumen diameter ≥2.5;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt;18 yr and &gt;80 yr;&#xD;
&#xD;
          -  Cardiac shock, multiple organ failure, cerebral hemorrhage, severe aortic stenosis and&#xD;
             myocardial infarction complications(cardiac rupture, ventricular septal rupture and&#xD;
             papillary muscle rupture);&#xD;
&#xD;
          -  Killip classification &gt;3, cardiognic shock, shore-infarction of culprit artery after&#xD;
             emergency PCI in 24 hours;&#xD;
&#xD;
          -  Previous documented allergic reaction to drug and device of this study;&#xD;
&#xD;
          -  Planned major surgery within 6 weeks in which impact DAPT;&#xD;
&#xD;
          -  Participation in another clinical study, interfering with this protocol Uncertain;&#xD;
&#xD;
          -  Life expectancy &lt; 1 year;&#xD;
&#xD;
          -  Any condition likely to interfere with study processes including follow-up visits or&#xD;
             increase of risk accessed by researcher.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yan Wang, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Trial Center of Xiamen Cardiovascular Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiang Chen, Dr</last_name>
    <phone>18033997788</phone>
    <email>Seanchenx@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Xiamen Cardiovascular Hospital Xiamen University</name>
      <address>
        <city>Xiamen</city>
        <state>Fujian</state>
        <zip>361000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yan Wang, Ph.D</last_name>
      <email>wy@medmail.com.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 24, 2021</study_first_submitted>
  <study_first_submitted_qc>May 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 8, 2021</study_first_posted>
  <last_update_submitted>May 29, 2021</last_update_submitted>
  <last_update_submitted_qc>May 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Xiamen Cardiovascular Hospital, Xiamen University</investigator_affiliation>
    <investigator_full_name>Yan Wang</investigator_full_name>
    <investigator_title>Prof</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

